Technology
Health
Pharmaceutical

Ritter Pharmaceuticals

$0.85
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

-$0.04 (-4.65%) Today
+$0.03 (3.66%) After Hours

Why Robinhood?

You can buy or sell RTTR and other stocks, options, ETFs, and crypto commission-free!

About

Ritter Pharmaceuticals, Inc. engages in the development of novel therapeutic products which modulate the human gut microbiome to treat gastrointestinal diseases. It focuses on the development and commercialization of RP-G28. Read More The company was founded by Andrew J. Ritter and Ira E. Ritter on March 29, 2004 and is headquartered in Los Angeles, CA.

Employees
7
Headquarters
Los Angeles, California
Founded
2004
Market Cap
4.95M
Price-Earnings Ratio
Dividend Yield
Average Volume
261.43K
High Today
$0.87
Low Today
$0.8192
Open Price
$0.868
Volume
91.00K
52 Week High
$4.00
52 Week Low
$0.47

Collections

Technology
Health
Pharmaceutical
2015 IPO
US
North America

News

NasdaqMay 7

Ritter Pharmaceuticals Completes Dosing of Last Patient in Pivotal 557-Subject Phase 3 Clinical Trial of RP-G28 in Patients with Lactose Intolerance

Top-line Data Readout on Target for early Q4 2019 LOS ANGELES, May 07, 2019 (GLOBE NEWSWIRE) -- Ritter Pharmaceuticals, Inc. (Nasdaq:RTTR) ("Ritter Pharmaceuticals" or the "Company"), a developer of innovative therapeutic products that modulate the gut microbiome to treat gastrointestinal diseases, today announced that the final patient in its first pivotal Phase 3 clinical trial of RP-G28 for the potential treatment of Lactose intolerance (LI), a study known as the "Liberatus" study (NCT03597516), h...

416
Simply Wall StApr 25

Ritter Pharmaceuticals, Inc. (NASDAQ:RTTR): What Are The Future Prospects?

The most recent earnings update Ritter Pharmaceuticals, Inc.’s (NASDAQ:RTTR) released in December 2018 showed company earnings became less negative compared to the previous year’s level – great news for investors Below, I’ve laid out key numbers on how market analysts predict Ritter Pharmaceuticals’s earnings growth trajectory over the next few years and whether the future looks brighter. Note that I will be looking at net income excluding extraordinary items to get a better understanding of the underlying ...

541

Earnings

-$1.66
-$1.12
-$0.59
-$0.05
Q3 2017
Q4 2017
Q1 2018
Q2 2018
Q3 2018
Q4 2018
Q1 2019
Estimated
-$0.72 per share
Actual
Expected May 24, After Hours
All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. Securities offered through Robinhood Financial LLC, member FINRA/SIPC. To learn more about the information provided on this page, please see our Web Disclosures.